Insmed to Present Cancer Data On rhIGFBP-3 In Herceptin-Resistant Breast Tumors at the 95th Annual Meeting of the American Association of Cancer Research
Tuesday March 23, 4:00 pm ET
RICHMOND, Va.--(BUSINESS WIRE)--March 23, 2004--Insmed Incorporated (Nasdaq:INSM - News) reported today that data from studies of the Company's anti-tumor agent, recombinant human insulin-like growth factor binding protein-3 (rhIGFBP-3), will be presented at the 95th Annual Meeting of the American Association for Cancer Research (AACR) to be held March 27-31 in Orlando at the Orange County Convention Center.
ADVERTISEMENT
The results of this study, published in the abstract titled, "The potential utility of recombinant human IGF binding protein-3 (rhIGFBP-3) for the treatment of HER-2-positive breast cancer," was conducted in the laboratory of Dr. Brian Leyland-Jones of McGill University and was designed to evaluate the anti-tumor activity of rhIGFBP-3 in a mouse model of Herceptin-resistant breast cancer. The study demonstrated the following:
1. As a single agent, rhIGFBP-3 inhibited Herceptin-resistant breast tumor growth by 67% compared to control, however, Herceptin only inhibited tumor growth by 30%.
2. The combination of agents inhibited breast tumor growth by 78%.
The abstract may be viewed at the Insmed corporate website, www.insmed.com. Click on "Product Pipeline" then click on the cancer development timeline arrow. For reprints, please contact Baxter Phillips at 804-565-3041 or bphillips@insmed.com.
IGFBP-3: A Naturally Occurring Anti-Cancer Agent
Our proprietary product, rhIGFBP-3, is a protein that is normally found in our bloodstream that has been shown to induce cancer cell death in a variety of experimental systems. Several studies have demonstrated that cancer risk increases with decreasing levels of circulating IGFBP-3. In addition, recent independent studies have demonstrated that IGFBP-3 can induce cell cycle arrest and enhance the efficacy of chemotherapeutic agents. Insmed is currently engaged in an active preclinical program with leading clinical oncologists and world experts in the field of IGFBP-3 research to evaluate the efficacy of rhIGFBP-3 as a therapeutic agent and to define the optimal clinical protocol in which to translate these promising observations into human clinical trials.
About Insmed
Insmed Incorporated develops pharmaceutical products for the treatment of metabolic and endocrine diseases with unmet medical needs. The Company's most advanced product candidate, the rhIGF-I/rhIGFBP-3 complex is a novel delivery composition of IGF-I that regulates essential metabolic and anabolic (growth promoting) processes, such as glucose uptake and tissue regeneration. Insmed is currently in a pivotal Phase III clinical trial for the rhIGF-I/rhIGFBP-3 complex for the treatment of Growth Hormone Insensitivity Syndrome (GHIS). The Company's second product candidate, rhIGFBP-3, is a recombinant protein that is being developed as an anti-cancer agent targeted towards the inhibition of solid tumor growth. Further information is available at the company's corporate website: www.insmed.com
About Herceptin®
Herceptin® is the first humanized antibody approved for the treatment of HER2 positive metastatic breast cancer. Herceptin® is designed to target and block the function of HER2 protein overexpression. Herceptin® is a registered trademark of Genentech (NYSE: DNA - News). |
